Abstract
Cocaine use disorder (CUD) is a worldwide problem with severe health and socio-economic consequences, which results in behavioral, cognitive, and neurobiological disturbances. Consensus on treatments are still under discussion, however, repetitive transcranial magnetic stimulation (rTMS) has been proposed as a promising treatment for medication-resistant disorders, including substance use disorders. Here, we describe the Mexican dataset of an rTMS clinical trial in patients with CUD (SUDMEX-TMS), a longitudinal dataset of 54 CUD participants (8 female) with five timepoints: baseline (T0), two weeks (T1), three months (T2), six months (T3) follow-up, and twelve months (T4) follow-up. Clinical rTMS treatment consisted of a double-blinded randomized clinical trial (n = 24 sham/30 active) for 2 weeks and open label afterwards, and includes demographic, clinical, and cognitive measures, as well as magnetic resonance imaging (MRI) acquisition in all timepoints: 1) structural (T1-weighted), 2) functional (resting state fMRI), and 3) multishell high-angular resolution diffusion-weighted (DWI-HARDI) sequences. The present dataset could be used to examine the impact of rTMS on CUD participants in clinical, cognitive, and multimodal MRI metrics in a longitudinal design.
Background and Summary
Cocaine use disorder (CUD) is a worldwide public health problem with severe socio-economic consequences 1. Clinical outcomes include attention, learning, and working memory deficit, impulsivity, and brain alterations 2, 3. Thus, developing effective treatments has been a major concern in clinical research. Pharmacological approaches along with psychosocial therapy are currently the standard treatment with low to moderate efficacy 4. Repetitive transcranial magnetic stimulation (rTMS) has gained popularity as a novel therapeutic intervention to reduce cocaine use and craving symptoms 5–7.
Current research is focused on trying to affect circuits underlying different addiction-related processes such as cue reactivity 8. Repeated TMS can activate these circuits and seems to induce neuroplastic changes in the meso-cortico-limbic system that can alter activity and connectivity 9. In addition, the use of neuroimaging techniques such as magnetic resonance imaging (MRI) has helped to study these neurobiological outcomes in the search for biomarkers of disorder status and treatment outcome.
Our dataset stems from our placebo-controlled double-blind randomized clinical trial (RCT) using rTMS as an add-on to treatment as usual (TAU). The main advantage of our dataset is that we acquired longitudinal psychiatric interviews with standard clinical assessment and multimodal MRI sequences, including multi-shell diffusion-weighted imaging (see box 1). A participants checklist with the specific MRI sequences acquired can be found in supplementary material. To date, the present dataset has been used to examine the short and long-term clinical benefits of rTMS and their impact on functional connectivity 10, to identify cognitive deficits of CUD participants by machine learning algorithms 11, to improve diffusion MRI segmentation methods using deep learning 12, to predict clinical outcomes using microstructural changes 13, and to identify a generalizable functional connectivity signature characterizes brain dysfunction in cocaine use disorder 14 . Altogether, this dataset could serve for the study of the longitudinal impact of rTMS as a promising add-on treatment for CUD, as well as to test new neuroimaging algorithms and analysis techniques.
Method
Participants
From a sample of n = 117 patients,54 patients were included in the study. Reasons for the dropouts are in Supplementary Material. The study ran from May 2017 to September 2019. The study was conducted at the Clinical Research Division of the National Institute of Psychiatry in Mexico City, Mexico. The study was approved by the Ethics Committee of the Instituto Nacional de Psiquiatría “Ramón de la Fuente Muñiz” (CEI/C/070/2016) and is in accordance with the latest version of the Declaration of Helsinki. The trial was registered at ClinicalTrials.gov (NCT02986438). All participants provided oral and written informed consent. Cocaine dependence was diagnosed in CUD patients using the MINI International Neuropsychiatric Interview-Plus Spanish version 5.0.0 15. Sample size was calculated using G*Power 16, for a 2 x 2 ANOVA (calculated from craving changes in previous cocaine rTMS studies 17), to attain 80% power at α = 0.05. Demographic characteristics between groups are summarized in Table 1.
Experimental design
The study consisted of four stages: 1) screening interview confirmed the criteria for substance use disorder (SUD) by a trained psychiatrist; 2) participants underwent a full clinical evaluation and initial MRI acquisition (baseline or T0); 3) Acute stage (RCT) where patients underwent regularly scheduled sessions (Active or Sham rTMS) for 10 days over 2 weeks (T1). The patients who received sham were invited to receive the active treatment, that is 10 additional days in a period of two weeks (T1-4); 4) finally, the open-label maintenance phase three months (T2), six months (T3) and 12 months (T4). Clinical and MRI data were collected at the time of, at four weeks only sham patients (T1-4), The study design is detailed in Figure 1.
SUDMEX-TMS experimental design. Clinical and MRI data were collected at the time of baseline (T0), at two weeks (T1), three months (T2), six months (T3) and 12 months (T4); * at four weeks only sham patients (T1-4).
Study dropout
Of the 54 recruited patients, 30 were randomly allocated to active treatment and 24 to sham rTMS. Five patients assigned to active rTMS and four patients assigned to sham discontinued the study, leaving 24 patients in the Active group and 20 in the Sham group who completed the acute phase. Finally, in the double-blind phase, 14 patients in the Sham group opted for compassionate use and received 2 weeks of acute phase rTMS treatment after the sham. In the maintenance phase: 1) 20 patients (15 initially allocated to Active and 5 to Sham) finished 3 months of twice-weekly rTMS sessions (T2); 2) 15 patients (initially 10 Active and 5 Sham) finished 6 months of rTMS sessions (T3); and 3) 7 patients (initially 4 Active and 3 Sham) finished 12 months of twice-weekly rTMS sessions (T4). Due to substantial attrition at T1 (2 weeks), when the study was at ∼30% completion, we changed the maintenance phase to last 6 months instead of 12 months for new participants after approval by the ethics committee. None of the patients who interrupted the treatment at any time reported adverse effects of rTMS.
Magnetic Resonance Imaging Acquisition
MRI sequences were acquired using a Philips Ingenia 3 T MR system (Philips Healthcare, Best, The Netherlands, and Boston, MA, USA), with a 32-channel dS Head coil. The order of the sequences was the following for the single session: 1) resting state (rs-fMRI), 2) T1-weighted (T1w), and 3) High Angular Resolution Diffusion Imaging (DWI-HARDI). This order was maintained across participants. Before the MRI acquisition, the amount of alcohol in participants’ blood was measured using a breathalyzer alcohol test and other substances were measured using breath alcohol test and Instant-viewTM multi drug urine test. The total scan time was approximately 50 min. During the study, the participants were fitted with MRI-compatible headphones and goggles.
Anatomical images
T1-weighted images were acquired using a 3D FFE SENSE sequence, TR/ TE = 7/3.5 ms, FOV = 240 mm2, matrix = 240 × 240 mm, 180 slices, gap = 0, plane = Sagittal, voxel = 1 × 1 × 1 mm (5 participants were acquired with a voxel size = 0.75 × 0.75 × 1 mm).
Diffusion-weighted imaging
The DWI-HARDI was a spin echo (SE) sequence, with TR/TE =9000/127 ms, FOV=230 mm2 (for 4 participants=224mm2), matrix=96 x 96 (for 4 participants=112 x 112), number of slices=57 (for 4 participants=58), gap=0, plane=axial, voxel=2.4 x 2.4 x 2.5 mm (for 4 participants=2 x 2 x 2.3 mm), directions: 8 = b0, 32 = b-value 1,000 s/mm2 and 96 = b-value 2,500 s/mm2 (for 4 participants: 96 = b-value 3,000 s/mm2), with a total of 136 directions. We acquired a DWI-HARDI with an opposite direction for field mappings using a SE EPI sequence with the following parameters: TR/TE=9000/127ms, flip angle=90°, matrix=128 x 128 (for 4 participants=112 x 112), voxel size=1.8 x 1.8 x 2.5mm (for 4 participants=2 x 2 x 2.3mm), number of slices=57 (for 4 participants=58), phase encoding direction=PA. A total of 7 b0 volumes were acquired.
Resting-state functional MRI
Resting state fMRI sequences were acquired using a gradient recalled (GE) echo planar imaging (EPI) sequence with the following parameters: dummies = 5, repetition time (TR)/echo time (TE)=2000/30.001ms, flip angle=75°, matrix=80x80, field of view=240mm2, voxel size=3 x 3 x 3mm, slice acquisition order=interleaved (ascending), number of slices=36, phase encoding direction=AP. The total scan time of the rs-fMRI session was 10 min, with a total of 300 volumes acquired. All participants were instructed to keep their eyes open, and to relax while not thinking about anything in particular. We used MRI-compatible goggles (fiber optic glasses SV-7021, Avotec) to show the participants a fixation cross (white cross with black background), and we used the included eye-tracking camera to prevent participants from falling asleep during this sequence. If the participants closed their eyes for more than 10 seconds, we would wake them up using the communication through the headphones, reminding them to try to not fall asleep for the 10 minutes the sequence lasted, and we re-started the sequence over. We acquired an opposite direction sequence for field mapping, using the same GE-EPI sequence with the following parameters: TR/TE=2000/30ms, flip angle=75°, matrix=80x80, voxel size=3x3x3mm, number of slices=36, phase encoding direction=PA. A total of 4 volumes were acquired.
Transcranial magnetic stimulation
We performed a placebo-controlled double-blind randomized controlled trial (RCT) with parallel groups (Sham/Real) for 2 weeks (acute phase) and an open-label maintenance phase for 6 months. For the acute phase, we used a MagPro R301Option magnetic stimulator and a figure-of-eight B65-A/P coil (MagVenture, Alpharetta, GA); for the maintenance phase, we used a MagPro R30 stimulator and a figure-of-eight MCF-B70 coil (MagVenture). The acute phase comprised 10 weekdays of 5,000 pulses per day (two sessions of 50 trains at 5 Hz, 50 pulses/train, 10 s inter-train interval, and 15 min inter-session interval). The maintenance phase comprised 3 and 6 months of 5,000 pulses per day, 2 sessions per week. The maintenance phase comprised two 5-Hz excitatory frequency (5000 pulses per day) sessions per week. The stimulation was delivered at 100% motor threshold to the left Dorso-Lateral Prefrontal Cortex (lDLPFC). The motor threshold was determined in each patient as described by Rossini et al. 18. We used a vitamin E capsule as a fiducial during MRI acquisition to identify the stimulation cortical target due to a lack of a brain navigator. In all rTMS sessions, we used either the 5.5 cm anatomic Rule or the Beam F3 method. We changed to the superior Beam F3 method after the first 16 participants to improve lDLPFC localization 19. Electrodes were applied to all patient’s left temporalis muscles to simulate muscular contraction in the sham group, enhancing the sham and blinding, you can find more details in the supplementary material.
Data Records
MRI Format Organization
The organization of the dataset follows the Brain Imaging Data Structure (BIDS, v. 1.0.1) (https://bids-specification.readthedocs.io/), commonly used to facilitate data sharing and project unifications by folder and file name structure according to sequence modality 20. Each MRI acquisition is shared in the Neuroimaging Informatics Technology Initiative (Nifti) format converted from Digital Imaging and Communication In Medicine (DICOM) using dcm2bids v.2.1.4. 21, along with data descriptions and metadata in JavaScript Object Notification files. The dataset is available and hosted on the OpenNeuro Data sharing platform (https://openneuro.org/datasets/ds003037) 22. Anonymization of the dataset was performed using pydeface to remove facial features 23.
Quality Control
To assess the quality of T1w and rsfMRI data, we used the MRI Quality Control tool (MRIQC) v.0.15, an automatic prediction of quality with visual reports of each sequence 24. For Diffusion-weighted images, we performed automated diffusion MRI QC (FSL EDDY_QC) to extract QC metrics sensitive and specific to artifacts 25.
Clinical measures
Patients were evaluated with a set of paper-based clinical tests at each session. The tests included were: 1) Mini International Neuropsychiatric Interview – Plus (MINI-Plus), 2) Addiction Severity Index (ASI), 3) Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II), 4) Symptom Checklist-90-Revised (SCL-R), 5) Cocaine Craving Questionnaire General (CCQ-G) and Now (CCQ-N), 6) World Health Organization Disability Assessment Schedule 2.0 (WHODAS), 7) Barratt Impulsiveness Scale v. 11 (BIS-11), 8) Edinburgh Handedness Inventory Short Form, 9) Hamilton Depression Rating Scale (HDRS), 10) Hamilton Anxiety Rating Scale (HARS), 11) Pittsburgh Sleep Quality Index (PSQI), 12) Cocaine Craving visual analog scale (VAS). These clinical tests were carried out by trained mental health psychologists and psychiatrists, in a quiet room without distractions. Summary of the acquired data are summarized in Table 2.
Mini International Neuropsychiatric Interview – Plus (M.I.N.I.-Plus)
The M.I.N.I. is a comprehensive diagnostic psychiatric interview designed to assess the 17 most common psychiatric disorders of the Axis I in DSM-IV and the ICD-10 26. We used the official Spanish translation version 5.0. of the M.I.N.I.-Plus, an extended version that includes a total of 23 psychiatric disorders. The interview consists of a set of structured questions that require a yes or no answer. These questions are designed to cover all the diagnostic criteria of the different psychiatric disorders. The interview is divided into modules that correspond to the diagnostic category which was applied by qualified psychiatrists.
Addiction severity index (ASI)
The ASI is a semi-structured interview designed to assess the lifetime and the past-30-days status in several functional domains: alcohol and drug use, medical and psychiatric health, employment, self-support, family relations, and illegal activities 27. We used the Spanish translation of the revised 5th edition 28.
Structured clinical interview for dsm-iv axis ii personality disorders (SCID-II)
The SCID-II is a psychiatric interview that allows the diagnosis of DSM-IV personality disorders 29. The instrument is a self-administered questionnaire that asks the DSM-IV Axis-II criteria in the form of yes/no questions. We only applied for this SCID-II questionnaire. First, it briefly characterizes the typical behavior, relationships, and capacity for self-reflection of the interviewee and then assesses each of the personality disorders. We used the official Spanish translation 30.
Symptom checklist-90-revised (SCL-90-R)
The SCL-90-R is a self-report measure of psychological symptoms and distress 31. It includes 9 symptom dimensions (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism) and 3 global indices of distress: Global Severity Index (GSI), Positive Symptom Distress Index (PSDI) and Positive Symptoms Total (PST). To score the instrument, an average of all the items for each symptom dimension is obtained. The GSI is calculated by calculating a global average of 90 items. The PSDI is the amount of non-zero responses given by the participant, while PST is calculated by the sum of the 90 items’ scores divided by the PSDI. In general, for the 9 symptom dimensions and the 3 global indices of distress, values above the 90th percentile are considered high, indicating a person at risk. We used a Spanish translation 32.
Cocaine craving questionnaire general (CCQ-General) and Now (CCQ-Now)
The CCQ is a 45-item questionnaire that explores cocaine craving among patients 33. The CCQ-General asks participants to rate their cravings over the previous week. The CCQ-Now asks participants about their cravings at the moment of assessment. Both versions of the CCQ consist of the same items, written in different tenses. The items are related to the following contents: the desire to use cocaine, intention and planning to use cocaine, anticipation of a positive outcome, the anticipation of relief from withdrawal or dysphoria, and lack of control overuse. We used the CCQ-General Spanish translation that was validated in the Mexican population 34.
World health organization disability assessment schedule 2.0 (WHODAS 2.0)
The WHODAS is an instrument designed to evaluate functional impairments or disabilities of patients with psychiatric disorders. The WHODAS 2.0 is an updated version of instrument 35. It provides information on four areas: Personal Care, Occupation, Family/Housing and Social Functioning. We used the official 36-item, self-administered, Spanish translation of this version 35, 36.
Barratt impulsiveness scale version 11 (BIS-11)
The 11th version of the Barratt Impulsivity Scale is one of the most widely used instruments for assessing impulsivity 37. This version of the scale consists of 30 items that describe impulsive and non-impulsive behaviors related to 3 main categories: attentional, motor, and non-planning/impulsiveness. We interpret the scores based on the following classification: highly impulsive (total score ≥ 72), within normal limits for impulsiveness (total score 52–71), extremely over-controlled, or has not honestly completed the questionnaire (total score <52) 38. We used the Spanish translation of the BIS-11 39.
Hamilton Depression Rating Scale (HDRS)
The Hamilton Rating Scale for Depression was used to provide a measure of the severity of depression. The version we used is one of 17 items. Its content focuses on the behavior of depression, with vegetative, cognitive, and anxiety symptoms having the greatest weight in the total calculation of the scale. The cutoff points to define severity are no depression (0-7); mild depression (8-16); moderate depression (17-23); and severe depression (≥24) 40.
Hamilton Anxiety Rating Scale (HARS)
This scale assesses the severity of anxiety globally and is useful for monitoring response to treatment. It consists of 14 items, to measure 13 anxious signs and symptoms, and the last one that evaluates the patient’s behavior during the interview. The interviewer scores from 0 to 4 points for each item, assessing both its intensity and frequency. The total score is the sum of those of each of the items. The range is from 0 to 56 points. The optimal HAM-A score ranges were: no/minimal anxiety ≤ 7; mild anxiety = 8-14; moderate = 15-23; severe ≥ 24 41 .
Pittsburgh Sleep Quality Index (PSQI)
This instrument has been developed to measure sleep quality in patients with psychiatric disorders. It is made up of 24 items, although only 19 are taken into account for its correction. In addition, it is divided into 7 dimensions: Subjective sleep quality, Sleep latency. Duration of sleep, Usual sleep efficiency, Sleep disturbances, Use of medication, Daytime dysfunction. It is answered with a Likert-type scale that goes from 0 to 4. For its correction, a sleep profile is obtained in each of the dimensions ranging from 0 to 3 and a total score that can range from 0 to 21 42.
Cocaine Craving visual analogue scale (VAS)
It is an instrument for the subjective assessment of the participant’s current craving. The visual scale consists of a continuous line of 10 cm (including 2 decimal places), where the left end refers to “no craving” and the right end to “the most intense craving” and the participants must mark with a cross the intensity of his craving he currently feels 43.
Instant-viewTM multi-drug urine test
Performed to identify the possible presence of substances of abuse in participants prior to performing the MRI study. This test was performed with an Instant-viewTM Multi Drug Urine Test (catalog number 03-3635) from Alpha Scientific Designs Inc (California, USA) https://www.alfascientific.com/products/multi-drug-urine-tests/, using the lateral flow chromatographic immunoassay technique. The substances detected and their cut-off points are as follows: Amphetamines (1000 ng/mL), Benzodiazepines (300 ng/mL), Cocaine (300 ng/mL), Methamphetamine (1000 ng/mL), Morphine/Opiates (2000 ng/mL), Marijuana/Hashish (50 ng/mL).
Cognitive tests
Patients were administered a comprehensive neuropsychological assessment at the three stages in two different modalities: computer-based using the Psychology Experiment Building Language (PEBL) version 2.0 with Spanish translation 44 and paper-based: 1) Berg’s Card Sorting Test, 2) Flanker Task, 3) Go/No-Go task, and 4) Letter-number test 44, 5) Digit span backward, 6) Iowa gambling task, 7) Tower of London, and 8) Reading the Mind in the Eyes Test. Both the Digit-Span Backward and 9) Letter-Numbers Sequencing exams were administered on paper. The cognitive tests were applied by a licensed psychologist in a quiet setting to minimize distractions. The assessment was conducted after the MRI scan 44, with a total duration of 45 minutes per participant. The tests were the following:
Cognitive flexibility
BCST or Berg’s Card Sorting Test: The Wisconsin Card Sorting Test for computers consists of a deck of 128 cards. The participants are shown one card at a time to match them into categories displayed on the screen (shape, color, or amount). The goal is for the participants to figure out the rule for categorizing. The rule changes when ten appropriately matched cards have been found 12, 13.
Inhibition
The flanker task assesses response inhibition processes by identifying stimuli over the noise. In a target-distracting sequence, participants are required to react to the middle arrow in a rapidly changing row of arrows while ignoring the others 45, 46 Go/No-go task: In this task, participants must give a prompt answer to a go signal and hold back their response to a no-go signal. Reaction time (RT) and the capacity to block the response under no-go signals are measured 47, 48.
Working memory
Letter-number sequencing: Participants are told a set of letters and numbers, which they must recall and repeat in the correct order, beginning with the numbers and going alphabetically up from there 49.
Digit span backward: Participants must recite a list of numbers in the reverse order that has been supplied by the examiner. The level of difficulty rises every two items and ends after two consecutive unsuccessful answers 49.
Decision Making
Iowa gambling task (IGT): Participants look at four digital card decks. They need to turn over one at a time to complete 100 trials. They need to identify the pattern of beneficial or unfavorable outcomes (receiving or losing a specific amount of money) and make their choice. The goal is to maximize earnings, out of the initial given amount of $2,000 50, 51.
Tower of London (ToLo) planning: This activity is frequently used to gauge planning ability and other executive functions. Participants must preplan a series of moves, one token at a time, to replicate the target model shown on the top board with the fewest number of movements 52, 53.
Theory of mind
The Reading the Mind in the Eyes Test (RMET): Participants are shown a grayscale image of the upper half face. They are required to choose from four options on the screen, which words describe the emotion or mental state of the image. A dictionary is available on the top screen in case participants are not familiar with any of the words 54
Technical Validation of the MRI
The automatic quality control of sMRI and rsMRI sequences was assessed using the MRIQC v.0.15 tool 24. For sMRI the extracted values were Signal-to-Noise Ratio (SNR) and Contrast-to-Noise Ratio (CNR) (Figure 2). SNR is related to the ratio of the mean voxel intensity of an image in contrast with the random noise intensity 55, whereas CNR measure is an extension of SNR that is not influenced by contrast changes 56.
Status of the structural weighted image of each MRI-Session (ses): baseline (T0), at two weeks (T1), three months (T2), and six months (T3), and patients that had 12 months (T4). The T14 time was for patients in the Sham group who decided to continue the clinical trial with open-label rTMS. The T14 refers to 2 weeks after T1 (4 weeks after T0). A) Signal-to-Noise Ratio (SNR), and B) Contrast-to-Noise Ratio (CNR).
For rsMRI the extracted values were Framewise Displacement (FD) and temporal Signal-to-Noise Ratio (tSNR) (Figure 3). FD is the sum of parameters of translational and rotational realignment of head motion 56, 57, while tSNR is calculated as the division of the mean of the time series by its standard deviation, when spatial resolution increases, TSNR decreases 58.
Status of the resting-state image of each MRI-Session (ses): baseline (T0), at two weeks (T1), three months (T2), and six months (T3), and patients that had 12 months (T4). The T14 time was for patients in the Sham group who decided to continue the clinical trial with open-label rTMS. The T14 refers to 2 weeks after T1 (4 weeks after T0). A) Mean Framewise Displacement (FD) and, B) Temporal Signal-to-Noise Ratio (tSNR).
For Diffusion-weighted images (dMRI), the quality of sequences was assessed using EDDY_QC a FSL tool 25, at a single level. The extracted values were related to motion: absolute (motion referenced to the middle time-point) and relative (motion compared with the previous time-point). The automated QC tool relies on EDDY 59, used to calculate the motion of dMRI data through volume-to-volume motion based on 6 parameters of the degree of freedom (Figure 4).
Participant motion of the diffusion-weighted image of each MRI-Session (ses): baseline (T0), at two weeks (T1), three months (T2), and six months (T3), and patients that had 12 months (T4). The T14 time was for patients in the Sham group who decided to continue the clinical trial with open-label rTMS. The T14 refers to 2 weeks after T1 (4 weeks after T0). A) Absolute motion, B) Relative motion.
Usage Notes
The present dataset consists of cocaine use disorder patients treated using rTMS therapy followed up to 12 months and divided into a sham group and an active rTMS group for the first 2 weeks. Uses include scientific/clinical research and academic purposes. Studies can be focused on the impact of rTMS over the active group in contrast to sham, on multimodal MRI data and/or clinical/cognitive measures. To use the present dataset in conjunction with larger-scale projects, such as those of the ENIGMA consortium, we recommend the use of an MRI-site harmonization technique such as ComBatHarmonization 60. Here, we provided QC information in order to facilitate data usage of which participants could be dismissed from data analysis. We recommend the use of artifact correction methods for preprocessing data due to the high motion of some subjects during scanning.
Data Availability
All data produced in the present study are available upon reasonable request to the authors, and all data produced are available online at
Code Availability
The MRI dataset can be found in https://openneuro.org/datasets/ds003037/. Please download the latest available version as there may be updates. Clinical and cognitive measures are available in Zenodo https://doi.org/10.5281/zenodo.7126853.
Author contributions
E.G.V. originated the concept of the dataset, designed the study, provided funding and acquired pilots. R.A.L, D.A.V., and V.V. recruited patients. D.A.V. and V.V. acquired the MRI data. D.A.V., and V.V. implemented the cognitive tests. R.A.L. implemented and managed the clinical part of the study. D.A.V., J.R.T., and C.A., performed the analysis and technical validation. D.A.V., J.R.T., A.F.V. and D.A.V., J.R.T., and E.G.V. created, reviewed and approved the manuscript.
Competing interests
The authors declare no conflict of interest.
Acknowledgments
We thank the people who helped this project in one way or another: Ernesto Reyes-Zamorano, Francisco J. Pellicer Graham, Erik Morelos-Santana, Sarael Alcauter, Luis Concha, Bernd Foerster, and Alejandra López-Castro. We also thank Rocio Estrada Ordoñez and Isabel Lizarindari Espinosa Luna at the Unidad de Atención Toxicológica Xochimilco for all their help and effort. Finally, we thank the study participants for their cooperation and patience. This study was supported by public funds CONACYT FOSISS No. 0260971 and CONACYT No. 253072. Diego Angeles-Valdez is a doctoral student from Programa de Maestría y Doctorado en Psicología, Universidad Nacional Autónoma de México (UNAM) and received fellowship No. 1003596 from Consejo Nacional de Ciencia y Tecnología (CONACYT). Jalil Rasgado Toledo is a doctoral student from the Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM) and received fellowship 858667 from CONACYT. This work received support from Luis Aguilar, Alejandro De León, and Jair García of the Laboratorio Nacional de Visualización Científica Avanzada, and also we appreciate the technical support by Leopoldo González-Santos
References
